Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ADH5 | P11766 | 1/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.38 |
| ▸ | RORC | P51449 | 4/20 | 0.38 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24860779 | 0.96 | PDE3B (0.47) | PDE3BPDE3AGAAADH5ACMSD | |
| SCHEMBL398435 | 0.88 | PDE3B (0.43) | PDE3BPDE3AACMSDAKR1C3AKR1C2 | |
| SCHEMBL3904050 | 0.84 | NOTUM (0.49) | PDE3BPDE3AALDH1A1 | |
| SCHEMBL6068947 | 0.81 | GAA (0.45) | GAAACMSDSRD5A2CLCN2RARB | |
| SCHEMBL22077172 | 0.80 | NOTUM (0.50) | PDE3BPDE3AALDH1A1 | |
| Hydrochloric Acid SCHEMBL9229512 | 0.80 | ADH5 (0.52) | GAAADH5SRD5A2AKR1C3AKR1C2 | |
| Hydrochloric Acid SCHEMBL7740677 | 0.80 | ADH5 (0.52) | GAAADH5SRD5A2AKR1C3AKR1C2 | |
| SCHEMBL27902795 | 0.80 | ACMSD (0.52) | GAAACMSDSRD5A2CLCN2ALDH1A1 | |
| SCHEMBL31395110 | 0.80 | PDE3B (0.44) | PDE3BPDE3AGAAACMSDCLCN2 | |
| SCHEMBL336261 | 0.78 | ADH5 (0.54) | GAAADH5SRD5A2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-20230212115-A1 | METHODS FOR THE PREPARATION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS AND SOLID FORME THEREOF | CIPLA LIMITED (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212115-A1 | METHODS FOR THE PREPARATION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS AND SOLID FORME THEREOF | CIPLA LIMITED (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4116294-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-01-11 | — | — | EP | disclosed |
| US-11390583-B2 | Process for preparation of Siponimod, its salts and solid state forms thereof | DR. REDDY'S LABORATORIES LIMITED (IN) | 2022-07-19 | — | — | US | disclosed |
| US-20200290961-A1 | PROCESS FOR PREPARATION OF SIPONIMOD, ITS SALTS AND SOLID STATE FORMS THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2020-09-17 | — | — | US | disclosed |
| US-20200290961-A1 | PROCESS FOR PREPARATION OF SIPONIMOD, ITS SALTS AND SOLID STATE FORMS THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2020-09-17 | — | — | US | disclosed |
| WO-2019064184-A1 | PROCESS FOR PREPARATION OF SIPONIMOD, ITS SALTS AND SOLID STATE FORMS THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-04-04 | — | — | WO | disclosed |
| US-20190047951-A1 | AZETIDINE MODULATORS OF THE SPHINGOSINE 1-PHOSPHATE RECEPTOR | AUSPEX PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-9604914-B2 | Process for preparing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-9604914-B2 | Process for preparing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| EP-2809645-A1 | PROCESS FOR PREPARING N-(4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXY)-ACETIMIDIC ACID ETHYL ESTER | Novartis AG (CH) | 2014-12-10 | — | — | EP | disclosed |
| WO-2013113915-A1 | PROCESS FOR PREPARING N-(4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXY)-ACETIMIDIC ACID ETHYL ESTER | NOVARTIS AG (CH) | 2013-08-08 | — | — | WO | disclosed |
| EP-2091950-B1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | disclosed |
| EP-2091950-B1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| WO-2008074820-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047951-A1 | AZETIDINE MODULATORS OF THE SPHINGOSINE 1-PHOSPHATE RECEPTOR | S1PR1, S1PR2, S1PR5 | PDE3B 627/4885PDE3A 470/4885GAA 1826/4885 |
| US-20230212115-A1 | METHODS FOR THE PREPARATION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS AND SOLID FORME THEREOF | S1PR1, S1PR2, S1PR3 | PDE3B 869/4885PDE3A 633/4885GAA 2556/4885 |
| US-11390583-B2 | Process for preparation of Siponimod, its salts and solid state forms thereof | SPHK2, S1PR4, SPHK1 | PDE3B 68/4885PDE3A 66/4885GAA 4021/4885 |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | AZI2, GABBR2, CNDP2 | PDE3B 849/4885PDE3A 474/4885GAA 1377/4885 |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | PDE3B 122/4885PDE3A 158/4885GAA 3869/4885 |
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | AZI2, GABBR2, CNDP2 | PDE3B 849/4885PDE3A 474/4885GAA 1377/4885 |
| US-20200290961-A1 | PROCESS FOR PREPARATION OF SIPONIMOD, ITS SALTS AND SOLID STATE FORMS THEREOF | SPHK2, S1PR4, SPHK1 | PDE3B 68/4885PDE3A 66/4885GAA 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.